Liver function, jaundice and hepatitis Flashcards

1
Q

Liver storage

A
Lglycogen (5% weight)
lipids (temporary, until lipoprotein secretion)
B12 and folate
Vitamin A stored as retinyl palmitate
ferritin and hemosiderin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Liver - role in metabolism

A

carb
amino acids
lipids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Liver - synthesis

A

plasma proteins
porphyrins (precursor for heme)
bile
hematopoiesis (fetal)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Liver - detox

A

ammonia converted to urea

CYP450 hydroxylation and oxidation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Glycogen synthesis pathway

A
  1. Glucose into cell via GLUT2
  2. Glucokinase phosphorylation to G1P
  3. Glycogen synthase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Glycogenolysis pathway

A
  1. Glycogen phosphorylase breaks alpha 1-4 linkage
  2. G1P to G6P
  3. G6P –> glucose (liver), or glycolysis (liver and skeletal muscle)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Glycolysis pathway

A
  1. Glucose to pyruvate

2. Pyruvate to lactate in cytoplasm, or to acetyl-CoA and into mitochondria for TCA cycle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Gluconeogenesis

A

can use lactate, amino acids (pyruvate or oxaloacetate), or glycerol (to trioses)
only in the liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Lactate clearance

A
  1. Glucose –> lactate in skeletal muscle
  2. Lactate –> glucose in liver

not energy-efficient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bile acid content

A
bile salt
electrolyte
phospholipids
proteins
cholesterol
bilirubin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bile acid function

A

digestion of dietary lipids –> micelles

excretion of waste products/drugs/toxins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Bile salt composition

A

derived from cholesterol, conjugated to glycine or taurine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Bilirubin production

A

In reticuloendothelial cells (spleen, liver):

  1. Heme –> biliverdin, CO, FE
  2. Biliverdin –> bilirubin
  3. Bilirubin (insoluble) binds albumin, transported to the liver
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Bilirubin metabolism in the liver

A
  1. Hepatocytes take up bilirubin without albumin via carrier
  2. Bilirubin binds ligandin in cytosol
  3. ER conjugates bilirubin to glucoronic acid, catalyzed by UDPGT
  4. Conjugated bilirubin diffuses out of ER to canalicular membrane/bile canaliculus (energy-dependent)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Bilirubin metabolism in gut

A
  1. Bilirubin in bile drains into duodenum
  2. In distal ileum & colon: hydrolyzed to unconjugated bilirubin by bacterial glucuronidases
  3. UC bilirubin reduced to urobilinogens by gut bacteria (colourless)

80-90% excreted in feces as urobilins
10-20% reabsorbed, re-excreted
small portion escapes hepatic uptake, excreted in urine
UC bilirubin is bound to albumin and cannot be filtered - not found in urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Bile enterohepatic circulation

A
  1. Hepatocytes synthesize bile acids using dietary cholesterol
  2. During interdigestive period, bile acids move down biliary tract, sequestered in gallbladder (sphincter of Oddi contracted, gallbladder wall relaxed)
  3. DUring digestion, intestinal mucosa simulated to secrete cholecystokinin –> contracts gallbladder wall, relaxes sphincter of Oddi –> bile acids flow into uodenum via ampulla of Vater
  4. Active transport systems in terminal ileum actively reabsorb bile acids into portal circulation (>90%)
  5. Bile acid lost replaced by hepatic biosynthesis using cholesterol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Vitamin B12 enterohepatic circulation

A
  1. Dietary vitamin B12 released by gastric acid
  2. B12 binds R-protein
  3. Pancreatic protease releases B12 from R-protein, binds IF secreted by parietal cells
  4. Terminal ilem actively takes up IF-B12 into portal circulation
  5. B12 complexed to transcobalamin
  6. Tissue takes up B12-TC complex; TC degraded in lysosome, B12 utilized

Primarily stored in the liver (50%) - excreted in bile but reabsorbed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Major transport proteins made by liver

A

Albumin
Transferrin
Ceruoplasmin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Major protease inhibitors made by liver

A

a1-antritrypsin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Major coagulation factors made by liver

A

fibrinogen, all clotting factors except VII

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Major immunoproteins made by liver

A

IgG (plasma cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

major complement protein made by liver

A

C3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Regulator of plasma protein synthesis

A

Low oncotic pressure
acute phase reaction (increase a1-AT, ceruloplasmin, C3, C4, decrease albumin and transferrin)
Estrogen (increase alpha1-AT, ceruloplasmin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Acetaminophen metabolism

A
  1. Oxidized by CYP 2E1 –> NAPQI
  2. Therapeutic> NAPQI –> glutathione, renally excreted
  3. High dose: binds cellular proteins

Toxicity: oxidative damage, mitochondrial dysfunction, inflammatory response –> injury/death of hepatocytes –> centrilobular liver necrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Acetaminophen toxicity management

A

Most deaths due to cerebral edema (hepatic encephalopathy)
60% survival with liver transplant

N-acetylcysteine infusion - >95% effective if started within 10 hours of ingestion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Jaundice definition

A

Yellowish pigmentation of the skin, conjunctival membranes over the sclerae and other mucous membranes due to hyperbilirubinemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Pre-hepatic jaundice pathophys

A

Due to hemolysis

Conjugating enzyme becomes saturated, UC bilirubin causes yellow skin discolouration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Hepatic jaundice pathophys

A

Gilberts hepatitis: reduced activity of glucuronyltransferase (conjugates bilirubin)

Viral: inflammation –> liver tissue destroyed and released

Drug: disruption of hepatocyte, transport proteins, cytolytic T_cell activation, apoptosis of hepatocytes, mitochondrial disruption, bile duct injury

Alcohol: hepatocyte death

Cirrhosis: fibrosis - blocks blood flow, liver does not remove enough bilirubin from blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Post-hepatic jaundice pathophys

A

Sex hormones

Promazines: obstructive jaundice

Cancer of the bile ducts/head of the pancreas, gallstones: intra/extrahepatic obstruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Hepatocellular injury labs

A

ALT and AST
ALT more specific to liver (look at creatinine kinase to differentiate with muscular cause)
>1000 IU/L –> acute viral hepatitis/drug toxicity/ischemic liver injury
Values may be smaller in fulminant due to death of hepatocytes
2)
Biliary obstruction <200

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Cholestasis labs

A

ALP and GGT - localized to the apical region of hepatocytes

Synthesized by impaired bile flow

32
Q

Jaundice labs

A

increase UC bilirubin: prehaptic
increase C bilirubin: hepatic/posthepatic
dark urine: only C bilirubin

33
Q

Chronic liver disease labs

A

albumin and INR

Hypoalbuminemia and coagulopathy seen when hepatic function impairment > 90%

34
Q

Hep A epidemiology

A

principally in children and young adults
worldwide
common in daycare, summer camp, NICU, military

35
Q

Hep A MOT

A

fecal-oral

36
Q

Hep A natural history

A

acute only, usually abrupt onset
complete recovery in 99%
fulminant in 1%
2-3 weeks

37
Q

Hep B epidemiology

A

high prevalence in SE asia, sub-Saharan Africa

high risk groups - MSM, IVDU, immigrants from endemic areas, etc

38
Q

Hep B MOT

A
parenteral
vertical transmission (almost 100%)
39
Q

Hep B natural history

A

complete recovery to progression to chronic (1-5%)
some progress to fulminant hepatitis
80-95% infected infants become chronic carriers (high risk for HCC)

40
Q

Hep C pathophys

A

immune-mediated cytolysis of virus-infected hepatocytes

also: fibrosing cholestatic hep C causes direct cytopathic effect

41
Q

Hep C epidemiology

A

worldwide
high risk group: 70% cases in NA are IVDU/transfusion
hemophiliacs treated <1987

42
Q

Hep C MOT

A

parenteral
vertical (2-5%)
breast milk (rare)

43
Q

Hep C natural history

A

Chronic hepatitis (70%)
wide range in rate of progression - avg 20% cirrhosis in 25 years
slower in younger, IVDU
faster in elderly, immunosuppressed, HIV+, alcohol

44
Q

HBsAg

A

acute and chronic infections

earliest indicator of acute hep B

45
Q

anti-HBs

A

previous exposure to HBV or vaccination

46
Q

anti-HBc, IgM

A

first antibody produced after infection with HBV

detects acute infection

47
Q

anti-HBC, total

A

acute and chronic HBV infections

persists for life

48
Q

HBeAg

A

found only when HBV is actively replicating
marker for infectivity
monitor treatment efficacy
some strains do not make e-antigen

49
Q

Anti-HBe

A

recovery from acute hep B

monitoring in chronic hep B

50
Q

HBV DNA

A

active HBV infection

monitor antiviral therapy in chronic patients

51
Q

HCV lab

A

RT-PCR for HCV-RNA

presence indicates active infection

52
Q

Hep A symptoms

A

often asymptomatic
flu like to fulminant hepatitis
Prodrome: anorexia, nausea/vomiting, headache, malaise, fatigue, diarrhea
overt hep A: sx for classic hepatitis, >2x in 6-10 wks
cholestaic hep A (10% symptomatic cases): prolonged pruritus, persistant jaundice
fulminant: rapid deterioration with signs of hepatic encephalopathy

53
Q

Hep A vaccination

A

pre-exposure: HAV

Post-exposure: HAV vaccine + optional co-adminstration of ISG

54
Q

Hep B vaccination

A

pre-exposure: recombinant HBsAg - very effective

55
Q

Hep B treatment

A

interferon alpha - chance of seroconversion
entecavir (NRTI)
tenofovir (NRTI)

56
Q

Interferon alpha MOA

A
  • cell becomes more resistant to viral infections
  • slows growth of rapidly proliferating cells
  • modulates immune system
  • inhibits viral replication
57
Q

Entecavir MOA

A

competes with the natural substrate to inhibit HBV polymerase

58
Q

Tenofovir MOA

A

inhibits HIV reverse transcriptase by competing with the natural substrate, terminates DNA chain

59
Q

Hep C medications

A

PEG-interferon, ribavirin

60
Q

Ribavirin MOA

A

nucleoside RNA-dependent RNA polymerase inhibitor
inhibits RNA-dependent RNA polymerase
RNA substrate analogue

61
Q

Interface hepatitis features

A

Inflammation and erosion of the hepatic parenchyma at its junction with portal tracts/fibrous septa

Cell death occurs at the interface between liver parenchyma and stroma = limiting plate

Inflammatory infiltrate composed of lymphocytes and accompanied by fibrosis of the affected areas

Common in chronic viral hepatitis

62
Q

Lobular hepatitis features

A

portal and periportal inflammation, with/without fibrosis
Sinusoids filled with lymphocytes
Kupffer cells serve as scavengers

63
Q

Hepatic fibrosis histo features

A

Consequence of the host immunological response
Loss of hepatocytes, microarchitecture, proliferation of hepatic fibroblasts, excess deposition of ECM

Activation and proliferation of hepatic stellate cells (Lipocyte/Ito cells) due to chornic liver injury
- contractile, produces ECM, secretes chemokines & cytokines

64
Q

Important steps in glycolysis

A

Initial: Glucokinase –> G6P (liver) (energy-requiring)

Phosphofructokinase (energy-requiring, unidirectional)

65
Q

Causes of lactic acidosis

A

Lack of oxygen in muscle tissue
Excessive muscle glycolysis
Impaired gluconeogenesis
ETC disorder

66
Q

Hep A incubation period

A

28-30 days

67
Q

Hep A communicability

A

maximum infectivity in latter half of incubation period to few days after onset of jaundice

68
Q

Hep A labs

A

Marked elevation in ALT >1000, before rise in bilirubin

69
Q

Hep B diagnosis

A

HBsAg 1-10 weeks after acute exposure
then appearance of anti-HBs and anti-HBc
HBe for replication and infectivity

70
Q

Vertical transmission of hep B clinical cours

A

1) Immune tolerant: ALT normal, HBe positive, high HBV DNA
2) Immune clearance: ~30yo. ALT elevation/inflammation, HBV DNA drops, observe variable flares
3) Inactive carrier: no inflammation, low HBV DNA. anti-HBe appears. Can stay in this forever, or
4) Reactivation: flares of disease. ALT goes up, virus level goes up, but anti-HBe always positive and HBeAg always negative

71
Q

Hepatitis D

A

RNA, needs HBV

High occurrence in eastern Europe and the middle east

72
Q

Types of hep D infection

A

co-infection with HBV - anti HDV IgM, HDV RNA, anti-HBc IgM positive

superinfection in HBV carrier - anti HBc IgM negative
worse prognosis and higher risk of HCC

73
Q

HDV treatment

A

PEG-interferon

74
Q

Intrinsic DILI

A

cause liver injury predictably in humans at a high dose

75
Q

Idiosyncratic DILI

A

affects susceptible individuals, variable presentations, less consistent relationship to dose

76
Q

R-value

A

ALT/ULN divided by ALK/ULN (upper limit normal)

Hepatocellular: R>5, cholestatic R<2